Abstract

VHHs usually display high physical and proteolytic stability, but in some cases stability needs to be increased further for their intended applications. The high thermal stability is due to the stable 3D structure of VHHs, which consists of a sandwich of nine beta-strands with a high number of intramolecular interactions, resulting in a very compact structure. Because of this compact structure, relatively low numbers of (basic) amino acids are accessible for proteases, explaining their usually high proteolytic stability. The high stability of VHHs is required when used as therapeutics given orally and nasally or when used as microbicides given, e.g., intra-vaginally. When given orally, VHHs should be stable at the low pH in the stomach and be resistant against all proteases in the intestines. Here a method is described to predict the proteolytic susceptibility of VHHs and to subsequently increase the proteolytic stability through genetic engineering.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.